A 52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ [hydrochlorothiazide], 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome.

Trial Profile

A 52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ [hydrochlorothiazide], 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2017

At a glance

  • Drugs Losartan (Primary) ; Losartan/hydrochlorothiazide (Primary)
  • Indications Hypertension; Metabolic syndrome
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jun 2009 Actual patient number changed from 1614 to 1738 as reported by ClinicalTrials.gov.
    • 05 Nov 2008 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top